Search

Displaying results 4331 - 4340 of 10000 in total
  1. Drug

    Propentofylline

    go.drugbank.com/drugs/DB06479
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    [L4537] It has been granted priority review, breakthrough therapy, and orphan drug designations for rare diseases based on the results of clinical trials.

    Products: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET
  3. Drug

    Chlorphenesin

    go.drugbank.com/drugs/DB00856
    Approved

  4. Drug

    Zinc protoporphyrin

    go.drugbank.com/drugs/DB03934
    Experimental

    Categories: Heterocyclic Compounds with 4 or More Rings
  5. Drug

    Denatonium

    go.drugbank.com/drugs/DB18588
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Pimobendan

    go.drugbank.com/drugs/DB11450
    ExperimentalVet approved

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Allisartan isoproxil

    go.drugbank.com/drugs/DB18880
    Investigational

    Allisartan isoproxil is under investigation in clinical trial NCT03264352 (Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes).

    Categories: Agents Acting on the Renin-Angiotensin System
  8. Drug

    Ammonium tetrathiomolybdate

    go.drugbank.com/drugs/DB17641
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  9. Drug

    Tricetin

    go.drugbank.com/drugs/DB08230
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Ibudilast

    go.drugbank.com/drugs/DB05266
    Investigational

    (codes: AV-411 or MN-166), but is approved for use as an antiinflammatory in Japan. … shrinkage in patients with relapsing-remitting (RR) and/or secondary progressive (SP) multiple sclerosis (MS).